000281861 001__ 281861
000281861 005__ 20251218103439.0
000281861 0247_ $$2doi$$a10.1016/j.bbr.2025.115858
000281861 0247_ $$2pmid$$apmid:41038324
000281861 0247_ $$2ISSN$$a0166-4328
000281861 0247_ $$2ISSN$$a1872-7549
000281861 037__ $$aDZNE-2025-01234
000281861 041__ $$aEnglish
000281861 082__ $$a610
000281861 1001_ $$aGroeger, Luise M$$b0
000281861 245__ $$aSerum and cerebrospinal kappa free light chains in psychiatric syndromes with neuronal and paraneoplastic autoantibodies.
000281861 260__ $$aAmsterdam$$bElsevier$$c2026
000281861 3367_ $$2DRIVER$$aarticle
000281861 3367_ $$2DataCite$$aOutput Types/Journal article
000281861 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1762417249_10696
000281861 3367_ $$2BibTeX$$aARTICLE
000281861 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000281861 3367_ $$00$$2EndNote$$aJournal Article
000281861 520__ $$aKappa free light chains (KFLC) are a surrogate parameter for intrathecal immunoglobulin G (IgG), immunoglobulin M (IgM) and immunoglobulin A (IgA) synthesis confirming neuroinflammation in the central nervous system (CNS). It is unclear whether KFLC can differentiate primary psychiatric disorders from neural autoantibody-associated psychiatric syndromes.We enrolled 76 patients with psychiatric diagnoses ICD-10 (International Classification of Diseases, 10th revision) (F00-09, F10-19, F20-29, F30-39, F40-49) and cerebrospinal fluid (CSF) as well as blood samples from our biobank. Commercial assays were used to determine neural autoantibodies. KFLC in serum and CSF samples were assessed by nephelometry (Siemens Atellica NEPH 630 analyzer). We calculated the relative intrathecal fraction (IF) of KFLC and the KFLC index using KFLC quotient and albumin quotient. Criteria for autoimmune encephalitis and autoimmune-mediated psychiatric syndromes were evaluated in patients to determine an autoimmune basis for the psychiatric symptoms.Neither the number of patients with elevated KFLC, a KFLC index nor the KFLC IF percentage served as an instrument for differentiating between autoantibody-positive (n = 18) and autoantibody-negative (n = 58) psychiatric patients. Patients with elevated KFLC levels in CSF had a higher proportion of lymphocytes than patients with non-elevated KFLC as a non-significant trend. We observed a non-significant trend towards higher CSF/serum IgM, but no trend for CSF/serum IgA or CSF/serum IgG ratio in patients with elevated KFLC levels than in those with non-elevated KFLC. No probable autoantibody-positive or seronegative autoimmune encephalitis was detected in patients. However, we observed an autoantibody-associated psychiatric syndrome in 6 out of 10 patients with elevated KFLC-IF, and the detection of elevated KFLC improved the diagnosis of probable autoimmune disease in 4 out of 10 patients (40 %).Elevated KFLC levels may indicate psychiatric patients presenting any intrathecal immunoglobulin synthesis and thus help to evaluate an autoimmune basis in psychiatric syndromes. Furthermore, it should be added as a novel criterion for intrathecal immunoglobulin synthesis in autoimmune-related psychiatric syndromes. Further large-scale research is needed to elucidate the role of KFLC in autoimmune-mediated psychiatric disorders and to verify the observed trends in CSF parameters in patients with elevated KFLC.
000281861 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000281861 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000281861 650_7 $$2Other$$aAutoantibodies
000281861 650_7 $$2Other$$aKappa free light chains
000281861 650_7 $$2Other$$aPsychiatry
000281861 650_7 $$2NLM Chemicals$$aAutoantibodies
000281861 650_7 $$2NLM Chemicals$$aImmunoglobulin kappa-Chains
000281861 650_7 $$2NLM Chemicals$$aBiomarkers
000281861 650_2 $$2MeSH$$aHumans
000281861 650_2 $$2MeSH$$aAutoantibodies: blood
000281861 650_2 $$2MeSH$$aAutoantibodies: cerebrospinal fluid
000281861 650_2 $$2MeSH$$aFemale
000281861 650_2 $$2MeSH$$aMale
000281861 650_2 $$2MeSH$$aMiddle Aged
000281861 650_2 $$2MeSH$$aAdult
000281861 650_2 $$2MeSH$$aMental Disorders: blood
000281861 650_2 $$2MeSH$$aMental Disorders: cerebrospinal fluid
000281861 650_2 $$2MeSH$$aMental Disorders: immunology
000281861 650_2 $$2MeSH$$aMental Disorders: diagnosis
000281861 650_2 $$2MeSH$$aAged
000281861 650_2 $$2MeSH$$aImmunoglobulin kappa-Chains: blood
000281861 650_2 $$2MeSH$$aImmunoglobulin kappa-Chains: cerebrospinal fluid
000281861 650_2 $$2MeSH$$aEncephalitis: immunology
000281861 650_2 $$2MeSH$$aEncephalitis: blood
000281861 650_2 $$2MeSH$$aEncephalitis: cerebrospinal fluid
000281861 650_2 $$2MeSH$$aEncephalitis: diagnosis
000281861 650_2 $$2MeSH$$aHashimoto Disease: blood
000281861 650_2 $$2MeSH$$aHashimoto Disease: cerebrospinal fluid
000281861 650_2 $$2MeSH$$aHashimoto Disease: immunology
000281861 650_2 $$2MeSH$$aHashimoto Disease: diagnosis
000281861 650_2 $$2MeSH$$aBiomarkers: blood
000281861 650_2 $$2MeSH$$aBiomarkers: cerebrospinal fluid
000281861 650_2 $$2MeSH$$aYoung Adult
000281861 7001_ $$aBrinke, Kristina Auf dem$$b1
000281861 7001_ $$aSimou, Amina$$b2
000281861 7001_ $$aLuedecke, Daniel$$b3
000281861 7001_ $$aMaier, Hannah B$$b4
000281861 7001_ $$aNeyazi, Alexandra$$b5
000281861 7001_ $$aGallinat, Jürgen$$b6
000281861 7001_ $$aBleich, Stefan$$b7
000281861 7001_ $$aSkripuletz, Thomas$$b8
000281861 7001_ $$aKonen, Franz F$$b9
000281861 7001_ $$0P:(DE-2719)2811317$$aWiltfang, Jens$$b10$$udzne
000281861 7001_ $$aMalchow, Berend$$b11
000281861 7001_ $$aFitzner, Dirk$$b12
000281861 7001_ $$aHansen, Niels$$b13
000281861 7001_ $$aCAP$$b14$$eCollaboration Author
000281861 773__ $$0PERI:(DE-600)2013604-3$$a10.1016/j.bbr.2025.115858$$gVol. 496, p. 115858 -$$p115858$$tBehavioural brain research$$v496$$x0166-4328$$y2026
000281861 8564_ $$uhttps://pub.dzne.de/record/281861/files/DZNE-2025-01234.pdf$$yOpenAccess
000281861 8564_ $$uhttps://pub.dzne.de/record/281861/files/DZNE-2025-01234.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000281861 909CO $$ooai:pub.dzne.de:281861$$popenaire$$popen_access$$pVDB$$pdriver$$pdnbdelivery
000281861 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811317$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b10$$kDZNE
000281861 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000281861 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-18
000281861 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-18
000281861 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-18
000281861 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-18
000281861 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-18
000281861 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBEHAV BRAIN RES : 2022$$d2024-12-18
000281861 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-18
000281861 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-18
000281861 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-18
000281861 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2024-12-18
000281861 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000281861 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-18
000281861 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-18
000281861 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000281861 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2024-12-18$$wger
000281861 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-18
000281861 9201_ $$0I:(DE-2719)1410006$$kAG Wiltfang$$lMolecular biomarkers for predictive diagnostics of neurodegenerative diseases$$x0
000281861 980__ $$ajournal
000281861 980__ $$aVDB
000281861 980__ $$aUNRESTRICTED
000281861 980__ $$aI:(DE-2719)1410006
000281861 9801_ $$aFullTexts